Liver protection health tablets and products thereof

Abstract

The present invention relates to the technical field of health care products, and in particular to liver protection health care tablets and products thereof. The present invention uses Hovenia dulcis, Euryale ferox, artichoke, turmeric, kudzu root, blueberry and wolfberry as fermentation raw materials, adjusts the raw material dosage relationship to optimize the liver protection effect; and uses Lactobacillus casei CICC 20363 and Weizmannella coagulans CICC 25219, and fermented to further enhance the liver protection effect; then, after post-treatment, mixed with xylitol, starch, and honey powder, and pressed into tablets, the liver protection health care tablets of the present invention are obtained.

Description

Technical Field

[0001] The invention relates to the technical field of health care products, and in particular to liver protection health care tablets and products thereof. Background Art

[0002] The liver is an important organ for human metabolism and detoxification, and is an important organ for the human hematopoietic and blood circulation system. It participates in all metabolic processes in the body, including the decomposition and excretion of a large number of trace elements needed by the body. In the process of metabolism, it synthesizes enzymes, which are easy to digest, absorb, detoxify and excrete.

[0003] With the development of economy, the improvement of people's living standards, the change of life and work style, the potential harm of chemical liver damage to the liver caused by excessive intake of alcohol, drugs, environmental pollution and food calories is becoming more and more serious. For example, the incidence of fatty liver and alcoholic liver is increasing year by year and there is a trend of younger people. Effective liver protection and health food is increasingly valued and welcomed by people. Therefore, providing an efficient liver protection health tablet is one of the technical problems that need to be solved at present. Summary of the invention

[0004] The present invention aims at the above technical problems and proposes a solution of the present invention. The solution of the present invention is in the technical field of health care products, specifically relates to liver protection health care tablets and products thereof.

[0005] The technical solution of the present invention is as follows:

[0006] In one aspect, the present invention provides a liver protection health care tablet, wherein the preparation method of the liver protection health care tablet comprises the following steps:

[0007] Step S1: crushing and sieving dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders; then mixing various powders according to 2.5-5.5 parts by mass of Hovenia dulcis, 0.5-2 parts by mass of Euryale ferox, 1.5-2.8 parts by mass of artichoke, 1-2 parts by mass of turmeric, 0.5-1.5 parts by mass of Pueraria lobata, 0.3-1 parts by mass of blueberry, and 0.3-1 parts by mass of wolfberry to obtain a mixed powder;

[0008] Step S2: mixing the mixed powder with water and glucose, sterilizing, and obtaining a mixed solution;

[0009] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at a temperature of 25-30° C. for 48-96 hours to obtain a fermentation material;

[0010] Step S4: sterilizing the fermented material, coarse filtering, and further fine filtering the coarse filtrate to obtain a fine filtrate;

[0011] Step S5: concentrating the refined filtrate under reduced pressure to obtain a concentrate, and freeze-drying the concentrate to obtain a dry material;

[0012] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into tablets to obtain the liver protection health tablets.

[0013] Furthermore, in step S1, each raw material is sieved to select powder with a particle size between 0.05-1 mm.

[0014] Furthermore, in step S1, the mass ratio of Hovenia dulcis powder to artichoke powder is 1.5-3:1.

[0015] Furthermore, in step S2, the mass ratio of the mixed powder to water is 1:15-50.

[0016] Furthermore, in step S2, glucose accounts for 3%-20% of the mass of the mixed powder.

[0017] Further, in step S3, the ratio of the number of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth is 1:2-4.

[0018] Further, in step S3, the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 in the fermentation broth were 1×10 5 -5×10 5 cfu / mL and 2×10 5 -1.5×10 6 cfu / mL.

[0019] Furthermore, Lactobacillus paracasei CICC 20363: China Industrial Microbiological Culture Collection Administration Center, Lactobacillus paracasei CICC 20363, number: CICC 20363.

[0020] Further, Weizmannia coagulans CICC 25219: China Industrial Microbiological Culture Collection Administration Center, Weizmannia coagulans CICC 25219, number: CICC 25219.

[0021] Furthermore, in step S4, the coarse filtration is performed by filtering with a filter membrane having a pore size of 5-20 microns.

[0022] Furthermore, in step S4, fine filtration is performed by filtering using a filter membrane with a pore size of 0.1-0.5 microns.

[0023] Furthermore, in step S5, the temperature of the reduced pressure concentration is 58-64°C.

[0024] Furthermore, in step S5, the concentrate is concentrated until the mass of the concentrate is 0.6-1.5 times of the mass of the mixture powder.

[0025] Furthermore, in step S5, the freeze-drying temperature is -40 to -25°C.

[0026] Furthermore, in step S5, freeze drying is performed until the water content is less than 5.2%.

[0027] Furthermore, in step S6, the mass ratio of xylitol to dry material is 5-8:1.

[0028] Furthermore, in step S6, the mass ratio of starch to dry material is 7-12:1.

[0029] Furthermore, in step S6, the mass ratio of honey powder to dry material is 1:0.5-2.

[0030] On the other hand, the present invention also provides a product prepared according to the liver protection health care tablet. Beneficial Effects

[0031] The invention adopts Hovenia dulcis, Euryale ferox, artichoke, turmeric, kudzu root, blueberry and wolfberry as fermentation raw materials, adjusts the raw material dosage relationship to optimize the liver protection effect; and uses fermentation bacteria composed of Lactobacillus paracasei CICC 20363 and Weizmannia coagulans CICC25219 to carry out fermentation to further improve the liver protection effect; and then the liver protection health care tablet is obtained through post-treatment and mixing with xylitol, starch and honey powder, and pressing into tablets.

[0032] After the rats in the alcoholic liver injury model group used the tablet product of the present invention, the contents of ALT, AST and TG active substances in the rat serum were significantly reduced, the activities of SOD and GSHPx in the liver tissue were significantly increased, and the MDA content was significantly reduced.

[0033] In the preparation system of the present invention, the combination of Hovenia dulcis and artichoke can further enhance the liver protection effect of the tablet. When the mass ratio of Hovenia dulcis powder to artichoke powder in the preparation raw material is in the range of 1.5-3:1, the liver protection effect of the tablet is better.

[0034] The present invention uses Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 to co-ferment Chinese herbal medicine, so that the prepared product has a good liver protection effect. The present invention uses Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 in the fermentation broth to produce a synergistic compound effect, which can effectively promote the liver protection effect, so that the ALT, AST, and TG active substance contents in the serum of rats in the alcoholic liver injury model group are significantly reduced, the SOD and GSHPx activities in the liver tissue are significantly increased, and the MDA content is significantly reduced. When the number ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth is 1:2-4, the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 are 1×10 5 -5×10 5 cfu / mL and 2×10 5 -1.5×10 6 cfu / mL, the resulting product has better liver protection effect. DETAILED DESCRIPTION

[0035] The present invention will be described below in conjunction with specific embodiments, and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments are used to illustrate the present invention, rather than to limit the present invention.

[0036] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.

[0037] 1. Preparation of Tablets

[0038] Lactobacillus paracasei CICC 20363: China Industrial Microbiological Culture Collection Administration Center, Lacticaseibacillus paracasei CICC 20363, number: CICC 20363.

[0039] Weizmannia coagulans CICC 25219: China Industrial Microbiological Culture Collection Administration Center, Weizmannia coagulans CICC 25219, number: CICC 25219.

[0040] Tablet 1:

[0041] The preparation method is as follows:

[0042] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 2.5 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0043] The mass ratio of Hovenia dulcis powder to artichoke powder is 2:1;

[0044] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0045] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0046] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:3, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 3×10 5 cfu / mL and 9×10 5 cfu / mL;

[0047] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0048] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0049] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0050] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0051] Tablet 2:

[0052] The preparation method is as follows:

[0053] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 5.6 parts by mass of Hovenia dulcis, 1.6 parts by mass of Euryale ferox, 1.9 parts by mass of artichoke, 1.7 parts by mass of turmeric, 1.15 parts by mass of Pueraria lobata, 0.7 parts by mass of blueberry, and 1 part by mass of wolfberry to obtain a mixed powder;

[0054] The mass ratio of Hovenia dulcis powder to artichoke powder is 2.95:1;

[0055] Step S2: mixing the mixed powder with water in an amount 24 times the mass of the mixed powder and glucose in an amount 6.5% the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0056] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at a temperature of 30° C. for 80 hours to obtain a fermentation material;

[0057] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:4, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 2.4×10 5 cfu / mL and 9.6×10 5 cfu / mL;

[0058] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0059] Step S5: concentrating the refined filtrate under reduced pressure at 58° C. to 0.88 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -32° C. to a water content of about 4.75% to obtain a dry material;

[0060] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0061] Among them, the mass ratio of xylitol to dry materials is 7.5:1, the mass ratio of starch to dry materials is 10.5:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0062] Tablet 3:

[0063] The preparation method is as follows:

[0064] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 0.8 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 6.7 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0065] The mass ratio of Hovenia dulcis powder to artichoke powder is 0.12:1;

[0066] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0067] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0068] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:3, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 3×10 5 cfu / mL and 9×10 5 cfu / mL;

[0069] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0070] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0071] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0072] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0073] Tablet 4:

[0074] The preparation method is as follows:

[0075] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 3.5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 4 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0076] The mass ratio of Hovenia dulcis powder to artichoke powder is 0.875:1;

[0077] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0078] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0079] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:3, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 3×10 5 cfu / mL and 9×10 5 cfu / mL;

[0080] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0081] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0082] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0083] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0084] Tablet 5:

[0085] The preparation method is as follows:

[0086] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 6.5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 1 part by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0087] The mass ratio of Hovenia dulcis powder to artichoke powder is 6.5:1;

[0088] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0089] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0090] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:3, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 3×10 5 cfu / mL and 9×10 5 cfu / mL;

[0091] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0092] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0093] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0094] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0095] Tablet 6:

[0096] The preparation method is as follows:

[0097] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 7 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 0.5 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0098] The mass ratio of Hovenia dulcis powder to artichoke powder is 14:1;

[0099] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0100] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0101] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:3, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 3×10 5 cfu / mL and 9×10 5 cfu / mL;

[0102] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0103] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0104] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0105] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0106] Tablet 7:

[0107] The preparation method is as follows:

[0108] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 2.5 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0109] The mass ratio of Hovenia dulcis powder to artichoke powder is 2:1;

[0110] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0111] Step S3: adding fermentation bacteria of Lactobacillus paracasei CICC 20363 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at a temperature of 28° C. for 72 hours to obtain a fermentation material;

[0112] Among them, the concentration of Lactobacillus casei CICC 20363 in the fermentation broth was 1.2×10 6 cfu / mL;

[0113] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0114] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0115] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0116] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0117] Tablet 8:

[0118] The preparation method is as follows:

[0119] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 2.5 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0120] The mass ratio of Hovenia dulcis powder to artichoke powder is 2:1;

[0121] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0122] Step S3: adding fermentation bacteria of Weizmannella coagulans CICC 25219 to the mixed solution to obtain a fermentation liquid; and then fermenting at a temperature of 28° C. for 72 hours to obtain a fermentation material;

[0123] Among them, the concentration of Weizmannella coagulans CICC 25219 in the fermentation broth was 1.2×10 6 cfu / mL;

[0124] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0125] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0126] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0127] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0128] Tablet 9:

[0129] The preparation method is as follows:

[0130] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 2.5 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0131] The mass ratio of Hovenia dulcis powder to artichoke powder is 2:1;

[0132] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0133] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0134] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:1, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 6×10 5 cfu / mL and 6×10 5 cfu / mL;

[0135] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0136] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0137] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0138] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0139] Tablet 10:

[0140] The preparation method is as follows:

[0141] Step S1: Grind and sieve dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders with a particle size of 0.05-1 mm; then mix the various powders according to 5 parts by mass of Hovenia dulcis, 1.8 parts by mass of Euryale ferox, 2.5 parts by mass of artichoke, 1.5 parts by mass of turmeric, 1.2 parts by mass of Pueraria lobata, 0.8 parts by mass of blueberry, and 0.9 parts by mass of wolfberry to obtain a mixed powder;

[0142] The mass ratio of Hovenia dulcis powder to artichoke powder is 2:1;

[0143] Step S2: mixing the mixed powder with water in an amount 25 times the mass of the mixed powder and glucose in an amount 6.2% of the mass of the mixed powder, and sterilizing the mixture to obtain a mixed solution;

[0144] Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at 28° C. for 72 hours to obtain a fermentation material;

[0145] The ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth was 1:7, and the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 1.5×10 5 cfu / mL and 1.05×10 6 cfu / mL;

[0146] Step S4: sterilizing the fermented material, filtering it through a filter membrane with a pore size of 10 microns for coarse filtration, and further filtering the coarse filtrate through a filter membrane with a pore size of 0.22 microns to obtain a fine filtrate;

[0147] Step S5: concentrating the refined filtrate under reduced pressure at 60° C. to 0.85 times the mass of the mixed powder to obtain a concentrate, and freeze-drying the concentrate at -30° C. to a water content of about 4.8% to obtain a dry material;

[0148] Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing them into a plurality of tablets to obtain the liver protection health tablets;

[0149] Among them, the mass ratio of xylitol to dry materials is 7:1, the mass ratio of starch to dry materials is 11:1, and the mass ratio of honey powder to dry materials is 1:0.8.

[0150] 2. Performance Test

[0151] The above liver protection health care tablets were tested for their effects.

[0152] 1. Liver protection effect experiment

[0153] The rat alcohol liver injury model was used to study the effect of the tablet of the present invention on the liver. The test indicators included: TG, ALT, AST, SOD, MDA and GSH-Px.

[0154] Among them, ALT and AST were detected by fully automatic biochemical analyzer; MDA was determined by TBA kit method; SOD was determined by xanthine oxidase kit method; GSH-Px was determined by DTNB spectrophotometry; TG was determined by KOH saponification-periodic acid oxidation kit method.

[0155] During the experiment: SD rats weighing 180-220 grams (half male and half female) were fed with ordinary feed for 1 week and then divided into groups; 10 blank control group and 110 modeling group. Among them, the blank control group rats continued to be fed with ordinary feed, gavaged with 10mL / kg / d of normal saline, and freely drank purified water; while the modeling group rats were randomly divided into model control group and tablet 1-10 group, with 10 rats in each group of modeling group. The modeling method was to use 50wt% ethanol aqueous solution 10mL / kg / d for gavage twice, the gavage time was 10 am and 10 pm, free drinking of 5wt% ethanol aqueous solution, and feeding with ordinary feed. The model group was gavaged with 10mL / kg / d of normal saline at the same time as modeling; the tablet 1-10 group was gavaged with 10g / kg / d tablet solution (the tablet solution was obtained by mixing 0.8g of the above tablet with 9.2g of purified water) at the same time as modeling; the gavage time was fixed at 3 pm every day. Each group of rats was killed after 45 days, and blood was collected from the abdominal vein for testing. The rats were fasted for 12 hours before blood collection and drank 5wt% ethanol solution freely. The liver of the rats killed was retained, and a small amount of tissue in the middle of the liver was taken to make a 30wt% liver homogenate using physiological saline, centrifuged, and the supernatant was taken for testing. The test results of TG, ALT, AST, SOD, MDA and GSH-Px of each group of rats are shown in Tables 1 and 2.

[0156] Table 1 TG, ALT, AST test results of each group

[0157] test TG / mmol / L ALT / U / L AST / U / L Blank control group 0.84±0.09 46.75±5.01 38.04±4.52 Model control group 1.61±0.16 55.17±4.95 49.04±5.13 Tablets 1 set 1.02±0.10 48.36±4.82 40.27±4.35 Tablets 2 sets 1.03±0.11 48.53±4.75 40.4±4.76 Tablets 3 groups 1.21±0.14 50.63±5.12 41.99±4.02 Tablets 4 groups 1.14±0.15 49.78±5.06 41.34±4.21 Tablets 5 groups 1.12±0.17 49.56±4.05 41.18±4.53 Tablets 6 groups 1.19±0.21 50.39±4.62 41.81±4.96 Tablets 7 groups 1.16±0.19 50.01±5.19 41.52±5.03 Tablets 8 groups 1.23±0.14 50.83±5.27 42.14±4.11 Tablets 9 groups 1.10±0.13 49.28±4.81 40.97±4.87 Tablets 10 sets 1.14±0.18 49.75±5.46 41.32±4.25

[0158] Table 2 Test results of SOD, MDA and GSH-Px in each group

[0159] test SOD / U / mL MDA / mmol / L GSH-Px / IU Blank control group 135.14±20.3 4.09±0.48 173.46±21.5 Model control group 101.57±18.2 7.68±0.86 120.94±12.7 Tablets 1 set 127.69±19.1 5.54±0.61 157.37±16.4 Tablets 2 sets 127.10±14.8 5.57±0.59 156.61±18.3 Tablets 3 groups 119.92±17.6 5.95±0.62 147.38±17.2 Tablets 4 groups 122.85±21.5 5.79±0.54 151.15±20.7 Tablets 5 groups 123.59±14.7 5.75±0.67 152.10±14.5 Tablets 6 groups 120.73±15.6 5.91±0.84 148.43±16.1 Tablets 7 groups 122.06±12.9 5.83±0.72 150.14±18.0 Tablets 8 groups 119.25±13.5 5.98±0.66 146.53±14.8 Tablets 9 groups 124.53±10.6 5.70±0.52 153.08±15.7 Tablets 10 sets 122.94±12.4 5.78±0.57 151.25±19.2

[0160] It can be seen from the test results in Table 1-2 that rats in the alcoholic liver injury model group had fatty degeneration and inflammation of liver tissue, and the content of ALT, AST, and TG active substances in serum increased significantly compared with the blank control group, the activity of SOD and GSHPx in liver tissue decreased significantly, and the MDA content increased significantly. After using the tablet product of the present invention, the content of ALT, AST, and TG active substances in rat serum decreased significantly, the activity of SOD and GSHPx in liver tissue increased significantly, and the MDA content decreased significantly. It can be seen that the liver protection health care tablets of the present invention have a good liver protection effect.

[0161] In the preparation system of the present invention, the combination of Hovenia dulcis and artichoke can further enhance the liver protection effect of the tablet. And from the test structures of tablet group 1 and groups 3-6, it can be seen that when the mass ratio of Hovenia dulcis powder to artichoke powder in the preparation raw material is in the range of 1.5-3:1, the liver protection effect of the tablet is better.

[0162] The present invention uses Lactobacillus casei CICC 20363 and Weizmannella coagulans CICC 25219 to co-ferment Chinese herbal medicine, so that the prepared product has a good liver protection effect. The present invention uses Lactobacillus casei CICC 20363 and Weizmannella coagulans CICC 25219 in the fermentation broth to produce a synergistic compound effect, which can effectively promote the liver protection effect, so that the ALT, AST, and TG active substance contents in the serum of rats in the alcoholic liver injury model group are significantly reduced, the SOD and GSHPx activities in the liver tissue are significantly increased, and the MDA content is significantly reduced. The above content can be obtained through the test results of tablet group 1 and 7-8 groups. When the number ratio of Lactobacillus casei CICC 20363 to Weizmannella coagulans CICC 25219 in the fermentation broth is 1:2-4, the concentrations of Lactobacillus casei CICC 20363 and Weizmannella coagulans CICC 25219 are 1×10 5 -5×10 5 cfu / mL and 2×10 5 -1.5×10 6 cfu / mL, the resulting product has better liver protection effect.

[0163] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A liver protection health care tablet, characterized in that: The preparation method of the liver protection health-care tablet comprises the following steps: Step S1: crushing and sieving dried Hovenia dulcis, Euryale ferox, artichoke, turmeric, Pueraria lobata, blueberry, and wolfberry respectively to obtain powders; then mixing various powders according to 2.5-5.5 parts by mass of Hovenia dulcis, 0.5-2 parts by mass of Euryale ferox, 1.5-2.8 parts by mass of artichoke, 1-2 parts by mass of turmeric, 0.5-1.5 parts by mass of Pueraria lobata, 0.3-1 parts by mass of blueberry, and 0.3-1 parts by mass of wolfberry to obtain a mixed powder; Step S2: mixing the mixed powder with water and glucose, sterilizing, and obtaining a mixed solution; Step S3: adding fermentation bacteria consisting of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 to the mixed solution to obtain a fermentation solution; and then fermenting the mixture at a temperature of 25-30° C. for 48-96 hours to obtain a fermentation material; Step S4: sterilizing the fermented material, coarse filtering, and further fine filtering the coarse filtrate to obtain a fine filtrate; Step S5: concentrating the refined filtrate under reduced pressure to obtain a concentrate, and freeze-drying the concentrate to obtain a dry material; Step S6: mixing the dried material with xylitol, starch and honey powder, and pressing into tablets to obtain the liver protection health tablets; The mass ratio of Hovenia dulcis powder to artichoke powder is 1.5-3:1; In the fermentation broth, the quantitative ratio of Lactobacillus paracasei CICC 20363 to Weizmannella coagulans CICC 25219 was 1:2-4; In the fermentation broth, the concentrations of Lactobacillus paracasei CICC 20363 and Weizmannella coagulans CICC 25219 were 1×10 5 -5×10 5 cfu / mL and 2×10 5 -1.5×10 6 cfu / mL.

2. The liver protection health care tablet according to claim 1, characterized in that: In step S2, the mass ratio of the mixed powder to water is 1:15-50.

3. The liver protection health care tablet according to claim 1, characterized in that: In step S2, glucose accounts for 3%-20% of the mass of the mixed powder.

4. The liver protection health care tablet according to claim 1, characterized in that: The concentrate is 0.6-1.5 times the mass of the mixed powder.

5. The liver protection health care tablet according to claim 1, characterized in that: The mass ratio of xylitol to dry materials is 5-8:1, and the mass ratio of starch to dry materials is 7-12:

1.

6. The liver protection health care tablet according to claim 1, characterized in that: The mass ratio of honey powder to dry material is 1:0.5-2.